rewrite this title and make it good for SEOBridgeBio Pharma, Inc. (BBIO) Discusses Achondroplasia Pathophysiology, Unmet Needs, and PROPEL 3 Infigratinib Phase 3 Study Transcript

Operator

Thank you for standing by. At this time, I would like to welcome everyone to the BridgeBio Pharma Achondroplasia Investor Webinar. [Operator Instructions]

I would now like to turn the call over to Justin To. You may begin.

Justin To

Good morning, and welcome to the BridgeBio webcast for the infigratinib program for achondroplasia. Before we begin today, I’d like to remind our audience that we will be making forward-looking statements today. For a discussion of these risks, please see BridgeBio’s most recent financial statements. This is an exciting time for a program as we have recently achieved last participant’s last visit for PROPEL 3, our Phase III clinical trial in achondroplasia, and we expect to announce top line results by the end of the first quarter.

Today, we are excited to be joined by Dr. Janet Legare, Professor in Genetics in the Department of Pediatrics at the University of Wisconsin School of Medicine and Public Health. She is also an investigator in the PROPEL 3 trial, and she is the Director of the Midwest Regional Bone Dysplasia Clinic, one of the largest of its kind in the United States. She will be providing an overview of achondroplasia, its genetic pathophysiology and unmet medical need.

We will then have Dr. Daniela Rogoff, who is the Chief Medical Officer of Skeletal Dysplasias